BioVie advances long COVID trial, top-line data expected by summer

About this episode

Cuong Do, CEO of BioVie, discusses the company's clinical efforts targeting long COVID and the significance of their research grant.

BioVie CEO Cuong Do joined Steve Darling from Proactive to provide an update on the company’s ongoing clinical efforts targeting long COVID, a condition that continues to affect an estimated 17 million Americans despite the acute phase of the COVID-19 pandemic having subsided. Do emphasized that long COVID remains a significant and persistent public health challenge, with many patients experiencing debilitating symptoms such as brain fog, chronic fatigue, and general malaise that can severely impact daily functioning and quality of life. He noted that unlike the initial viral infection, long COVID appears to involve lingering viral protein fragments or related biological remnants that may continue to stimulate the immune system even after the virus has been cleared from the body. This ongoing immune activation is believed to contribute to sustained inflammation, which in turn may drive the neurological and systemic symptoms associated with the condition. BioVie Inc. is focusing its research efforts specifically on addressing these central nervous system-related symptoms through a targeted therapeutic approach. Do highlighted that the company’s program is supported by a $13…

People in this episode

Host: Steve Darling

Guest: Cuong Do

Topics covered

• long COVID
• clinical trials
• public health
• neurological symptoms
• therapeutic approaches

Keywords

• long COVID
• BioVie
• clinical trial
• neurological symptoms
• immune system
• chronic fatigue
• brain fog
• public health

Mentioned in this episode

Organizations: BioVie

Places: United States

More episodes of Proactive - Interviews for investors

• Regan Capital CIO on bond market opportunities in a rising rate environment · June 12, 2026 · 6 min
• Light Science Technologies lifts capacity 50% with new SMT line and global client win · June 12, 2026 · 5 min
• Poolbeg Pharma launches POLB 001 TOPICAL trial to tackle CAR-T side effects · June 12, 2026 · 4 min
• Lumos Diagnostics expands FebriDx adoption across 100+ US healthcare sites with CLIA Waiver · June 11, 2026 · 8 min
• Flow Metals advances drill-ready Yukon gold project while expanding Copper exploration in B.C. · June 11, 2026 · 6 min
• Midstream energy sector positioned for growth as LNG and AI drive demand · June 11, 2026 · 7 min